Strengthening the Development Pipeline through Open Innovation

「In nucleic acid medicines, we are concentrating on drug discovery research for siRNA medicines with a view to securing a competitive advantage, while actively recruiting highly specialized personnel and acquiring drug discovery technologies. In cell therapies, we are partnering with companies that possess expertise and technologies in regenerative medicine and advancing the development of treatments using SHED, stem cells from human exfoliated deciduous teeth, and REC, highly purified mesenchymal stem cells.」

「In nucleic acid medicines, we are concentrating on drug discovery research for siRNA medicines with a view to securing a competitive advantage, while actively recruiting highly specialized personnel and acquiring drug discovery technologies. In cell therapies, we are partnering with companies that possess expertise and technologies in regenerative medicine and advancing the development of treatments using SHED, stem cells from human exfoliated deciduous teeth, and REC, highly purified mesenchymal stem cells.」

「We continued preparations for the Phase III clinical trial of HLC-001 and submitted the clinical trial notification in January 2026.」

「In research, the company is working to strengthen its drug discovery pipeline by incorporating new modalities, including cells, nucleic acids and genes, through the promotion of open innovation and drug discovery using external resources.」

「The Group is pursuing R&D activities focused primarily on prescription pharmaceuticals while actively promoting R&D partnerships with companies in Japan and overseas, in keeping with its corporate motto, “Foresight, originality and research.” There were no material changes in the status of the Group’s R&D activities during the interim consolidated accounting period.」

「In research, the company is working to strengthen its drug discovery pipeline by incorporating new modalities, including cells, nucleic acids and genes, through the promotion of open innovation and drug discovery using external resources. In particular, for nucleic acid medicines, it is actively recruiting personnel with advanced expertise and acquiring drug discovery technologies to advance drug discovery research with competitive advantages. In regenerative medicine products, it is giving priority to projects using mesenchymal stem cells and developing treatments based on human dental pulp stem cells (SHED) and high-purity mesenchymal stem cells (REC). Following the achievement of the primary endpoint in a Phase II clinical trial conducted by Human Life Code Co., Ltd. for HLC-001, an umbilical cord-derived cell product, for noninfectious pulmonary complications after hematopoietic stem cell transplantation, the company is preparing for the next stage.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「In research, the company is working to strengthen its drug discovery pipeline by incorporating new modalities, including cells, nucleic acids and genes, through the promotion of open innovation and drug discovery using external resources. Regenerative medicine products are one of its priority areas, and it is giving priority to projects using mesenchymal stem cells.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「In research, the company is conducting drug discovery research to strengthen its development pipeline by introducing early-stage development candidates through the promotion of open innovation and other initiatives. It is also actively pursuing out-licensing activities for schizophrenia treatments and pain treatments (TRPV1 antagonists).」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「In research, the company is conducting drug discovery research to strengthen its development pipeline by introducing early-stage development candidates through the promotion of open innovation and other initiatives. It is also actively pursuing out-licensing activities for schizophrenia treatments and pain treatments (TRPV1 antagonists). In clinical development, the novel high-purity EPA formulation MND-2119, the pediatric indication for Lialda, the pediatric indication for Lexapro, and the antidepressant MD-120, which is being co-developed with Pfizer Inc., are each in Phase III clinical development.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「In research, we are engaged in drug discovery research activities to enhance the development pipeline by introducing early-stage development candidates and other products through the promotion of open innovation.」

「Our Group practices its corporate philosophy of “foresight, originality and research” and conducts research and development activities centered on prescription medicines while actively promoting research and development partnerships with companies in Japan and overseas. It is also stated that there were no significant changes in the status of the Group’s research and development activities during the nine-month period of the consolidated fiscal year.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「In research, we are engaged in drug discovery research activities to enhance the development pipeline by introducing early-stage development candidates and other products through the promotion of open innovation.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「In drug discovery research, we will enhance the development pipeline by introducing early-stage development candidates and other products through the promotion of open innovation.」

「We will shift our research policy toward enhancing our development pipeline by introducing development candidates and other products through the promotion of open innovation and other initiatives.」